Home › Funds › Pacific Wealth Management › HALO
Pacific Wealth Management position in HALO
HALOZYME THERAPEUTICS INC · Health Care
Pacific Wealth Management reported holding 2,184 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$241K, representing 0.11% of its reported portfolio and ranking #20 among its reported holdings. Pacific Wealth Management has disclosed HALO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Pacific Wealth Management's HALO position evolved
Pacific Wealth Management first disclosed a stake in HALO in Q1 2026 at 5,401 shares (US$349K). The position peaked in Q2 2026 at 5,401 shares, worth US$423K. Across 3 filings, Pacific Wealth Management increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,184 shares valued at US$241K — a reduction of -3,217 shares quarter over quarter.. Notable position changes include a 60% trim in Q3 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 5.40K | $349.07K | New |
| Q2 2026 | 5.40K | $422.74K | Hold |
| Q3 2026 | 2.18K | $241.11K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HALO and 13F data
HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$196.5M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HALO
- CONGRESS ASSET MANAGEMENT CO 2.28M sh · $251.89M · Q3 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 2.51M sh · $196.54M · Q2 2026
- SNYDER CAPITAL MANAGEMENT L P 2.40M sh · $187.54M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 1.94M sh · $151.69M · Q2 2026
- WASATCH ADVISORS LP 1.05M sh · $115.88M · Q3 2026
- Stephens Investment Management Group LLC 1.39M sh · $109.02M · Q2 2026
- GW&K Investment Management, LLC 1.35M sh · $105.97M · Q2 2026
- Boston Trust Walden Corp 1.08M sh · $84.77M · Q2 2026
- LMR Partners LLP 45.00M sh · $65.81M · Q2 2026
- Mizuho Markets Cayman LP 834.50K sh · $65.32M · Q2 2026
More on Pacific Wealth Management
FAQ
How long has Pacific Wealth Management held HALO?
Pacific Wealth Management has disclosed HALO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Pacific Wealth Management's current position in HALO?
As of Q3 2026, Pacific Wealth Management holds 2.18K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $241.11K, representing 0.11% of its reported portfolio and ranking #20.
Has Pacific Wealth Management been buying or selling HALO?
In the latest 13F filing (Q3 2026), Pacific Wealth Management reduced its position in HALO. The position peaked in Q2 2026 at 5.40K shares.
Which other funds hold HALO?
Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.